CYP1A1, CYP1A2 and CYBA gene polymorphisms associated with oxidative stress in COPD

Clinica Chimica Acta

Volumn 411, Issue 7-8, 2010, Pages 474-480

  Vibhuti, Arpana ^a   Arif, Ehtesham ^a   Mishra, Aastha ^a   Deepak, Desh ^b   Singh, Bhawani ^b   Rahman, Irfan ^c   Mohammad, Ghulam ^d   Pasha, M A Qadar ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d SNM Hospital   (India)

Author keywords

COPD; CYBA; CYP1A1; CYP1A2; Polymorphism

Indexed keywords

CATALASE; CYTOCHROME; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; GLUTATHIONE; GLUTATHIONE PEROXIDASE; ISOLEUCINE; LIPID PEROXIDASE; MALONALDEHYDE; PROTEIN CYBA; UNCLASSIFIED DRUG; VALINE;

ADULT; ALLELE; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL;

ADULT; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NADPH OXIDASE; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77649186280     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.12.018     Document Type: Article

References (43)

1. Murray C.J.L., Lopez A.D. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997, 349:1269-1276.
2. Rahman I., Adcock I.M. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006, 28:219-242.
3. Rahman I. Oxidative stress in pathogenesis of COPD: cellular and molecular mechanisms. Cell Biochem Biophys 2005, 43:167-188.
4. Rahman I., van Schadewijk A.A., Crowther A.J., et al. 4-hydroxy-2-nonenal, a specific lipid peroxidation product, is increased in lungs of patients with COPD. Am J Respir Crit Care Med 2002, 166:490-495.
5. Harju T., Kaarteenaho-Wiik R., Soini Y., et al. Diminished immunoreactivity of gamma-glutamylcysteine synthetase in the airways of smoker's lung. Am J Respir Crit Care Med 2002, 166:754-759.
6. Rahman I., Biswas S.K., Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006, 533:222-239.
7. Sethi J.M., Rochester C.L. Smoking and chronic obstructive pulmonary disease. Clin Chest Med 2000, 21:67-86.
8. Snider G.L. Chronic obstructive pulmonary disease: risk factors, pathophysiology and pathogenesis. Annu Rev Med 1989, 40:411-429.
9. Vibhuti A., Arif E., Deepak D., et al. Correlation of oxidative status with BMI and lung function in COPD. Clin Biochem 2007, 40:958-963.
10. Hoidal J.R., Fox R.B., LeMarbe P.A., et al. Altered oxidative metabolic responses in vitro of alveolar macrophages from asymptomatic cigarette smokers. Am Rev Respir Dis 1981, 123:85-89.
11. Siedlinski M., Postma D.S., van Diemen C.C., Blokstra A., Smit H.A., Boezen H.M. Lung function loss, smoking, vitamin C intake, and polymorphisms of the glutamate-cysteine ligase genes. Am J Respir Crit Care Med 2008, 178:13-19.
12. Bentley A.R., Emrani P., Cassano P.A. Genetic variation and gene expression in antioxidant-related enzymes and risk of COPD: a systematic review. Thorax 2008, 63:956-961.
13. Chappell S., Daly L., Mogan K., et al. Genetic varients of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD. Eur Respir J 2008, 32:931-937.
14. Gonzalez F.J. Molecular genetics of the P-450 superfamily. Pharmacol Ther 1990, 45:1-38.
15. Turesky R.J., Constable A., Richoz J., et al. Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome p450 1A2. Chem Res Toxicol 1998, 11:925-936.
16. Hammons G.J., Milton D., Stepps K., et al. Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Carcinogenesis 1997, 18:851-854.
17. Brennan L.A., Steinhorn R.H., Wedgwood S., et al. Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: a role for NADPH oxidase. Circ Res 2003, 92:683-691.
18. Ushio-Fukai M., Zafari A.M., Fukui T., et al. p22 phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996, 271:23317-23321.
19. Ahsan A., Ram R.B., Baig M.A., et al. ACE I allele and eNOS G allele crosstalk may have a role in chronic obstructive pulmonary disease. Clin Biochem 2004, 37:1037-1040.
20. Vibhuti A., Arif E., Deepak D., et al. Genetic polymorphisms of GSTP1 and mEPHX correlate with oxidative stress markers and lung function in COPD. Biochem Biophys Res Commun 2007, 359:136-142.
21. Arif E., Ahsan A., Vibhuti A., et al. Endothelial nitric oxide synthase gene variants contribute to oxidative stress in COPD. Biochem Biophys Res Commun 2007, 361:182-188.
22. Arif E., Vibhuti A., Alam P., et al. Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clin Chim Acta 2007, 382:37-42.
23. Oyama T., Mitsudomi T., Kawamoto T., et al. Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP 1A1 genotypes in Japanese. Int Arch Occup Environ Health 1995, 67:253-256.
24. Cosma G., Crofts F., Taioli E., et al. Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 1993, 40:309-316.
25. Landi M.T., Bertazzi P.A., Shields P.G., et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994, 4:242-246.
26. San Jose G., Moreno M.U., Olivan S., et al. Functional effect of the p22phox -930A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. Hypertension 2004, 44:163-169.
27. Guzik T.J., West N.E.J., Black E. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000, 102:1744-1747.
28. American Thoracic Society Standardization of spirometry. Am Rev Respir Dis 1987, 136:1285-1298.
29. Light R.W., Conrad S.A., George R.B. The one best test for evaluating the effects of bronchodilator therapy. Chest 1977, 72:512-516.
30. Reis A.L. Response to bronchodilators. Pulmonary Function Testing: Guidelines and Controversies 1982, 15-221. Academics Press, New York.
31. Millar S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
32. Kawajiri K., Nakachi K., Imai K., et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990, 263:131-133.
33. Nakajima M., Yokoi T., Mizutani M., et al. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999, 125:803-808.
34. Moreno M.U., San Jose G., Orbe J., et al. Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett 2003, 542:27-31.
35. Inoue N., Kawashima S., Kanazawa K., et al. Polymorphism of the NADH/NADPH oxidase p22phox gene in patients with coronary artery disease. Circulation 1998, 97:135-137.
36. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68:978-989.
37. Bartsch H., Nair U., Risch A., et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000, 9:3-28.
38. Cai H., Duarte N., Wilcken D.E., et al. NADH/NADPH oxidase p22phox C242T polymorphism and coronary artery disease in the Australian population. Eur J Clin Invest 1999, 29:744-748.
39. Frazer K.A., Ballinger D.G., Cox D.R., et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449:851-861.
40. Chang B., Zheng S.L., Isaacs S.D. Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. Int J Cancer 2003, 106:375-378.
41. Ioannides C. Enzymes systems that metabolise drugs and other xenobiotics 2001, 567. Wiley, UK.
42. Lee J.M., Moehlenkamp J.D., Hanson J.M., et al. Nrf2-dependent activation of the antioxidant responsive element by tert-butylhydroquinone is independent of oxidative stress in IMR-32 human neuroblastoma cells. Biochem Biophys Res Commun 2001, 280:286-292.
43. Lee J.M., Johnson J.A. An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 2004, 37:139-143.